LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Analysts

LeMaitre Vascular, Inc. (NASDAQ:LMAT) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $112.60.

A number of equities research analysts have recently commented on LMAT shares. Weiss Ratings cut LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 6th. Freedom Capital raised shares of LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Zacks Research raised shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Barrington Research lifted their price target on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 5,044 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the transaction, the director owned 3,942 shares in the company, valued at approximately $437,956.20. The trade was a 56.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the transaction, the insider owned 3,749 shares of the company’s stock, valued at approximately $401,143. The trade was a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 269,891 shares of company stock worth $28,969,086 over the last ninety days. Insiders own 7.40% of the company’s stock.

Hedge Funds Weigh In On LeMaitre Vascular

Large investors have recently bought and sold shares of the stock. Sound Income Strategies LLC boosted its stake in LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC purchased a new stake in shares of LeMaitre Vascular in the first quarter valued at about $32,000. Cornerstone Planning Group LLC raised its holdings in LeMaitre Vascular by 534.0% during the third quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 283 shares in the last quarter. MAI Capital Management purchased a new position in LeMaitre Vascular during the third quarter worth about $38,000. Finally, First Horizon Corp purchased a new position in LeMaitre Vascular during the third quarter worth about $39,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $97.31 on Monday. The business’s 50-day moving average is $109.34 and its two-hundred day moving average is $94.94. The company has a market capitalization of $2.22 billion, a P/E ratio of 35.91, a P/E/G ratio of 2.70 and a beta of 0.60. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular has a fifty-two week low of $78.35 and a fifty-two week high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. During the same period last year, the firm earned $0.48 EPS. The firm’s revenue for the quarter was up 11.1% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Research analysts predict that LeMaitre Vascular will post 3 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.